Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
TTF-1/Thyroid Transcription Factor 1/NKX2-1 CRISPR/Cas9 KO Plasmid (h): sc-400458
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TTF-1/Thyroid Transcription Factor 1/NKX2-1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the TTF-1/Thyroid Transcription Factor 1/NKX2-1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TTF-1/Thyroid Transcription Factor 1/NKX2-1 Antibody (8G7G3/1): sc-53136
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TTF-1/Thyroid Transcription Factor 1/NKX2-1 CRISPR/Cas9 KO Plasmid (h) | sc-400458 | 20 µg | $397.00 |
Overview
NKX2-1 (TTF-1, thyroid transcription factor 1) encodes a homeobox DNA-binding transcription factor that establishes and maintains lineage programs in the developing and adult thyroid, lung epithelium, and ventral forebrain. It regulates gene networks controlling epithelial differentiation, surfactant homeostasis, and organ morphogenesis, coordinating transcriptional states that intersect with developmental signaling pathways such as Wnt, BMP, and FGF. In human disease biology, altered NKX2-1 dosage or mutation is linked to congenital brain–lung–thyroid phenotypes and contributes to context-dependent transcriptional rewiring in pulmonary and thyroid pathology. Because NKX2-1 functions as a master regulator of cell identity, it is frequently studied in differentiation models, epithelial state transitions, and oncogenic lineage dependency mechanisms.
TTF-1/Thyroid Transcription Factor 1/NKX2-1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the NKX2-1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the NKX2-1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the NKX2-1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TTF-1/Thyroid Transcription Factor 1/NKX2-1 protein expression.
This CRISPR knockout system enables efficient generation of NKX2-1-deficient cell models for investigation of TTF-1/Thyroid Transcription Factor 1/NKX2-1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting NKX2-1 exon(s) critical for TTF-1/Thyroid Transcription Factor 1/NKX2-1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple NKX2-1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by TTF-1/Thyroid Transcription Factor 1/NKX2-1 CRISPR/Cas9 KO Plasmid (h) and TTF-1/Thyroid Transcription Factor 1/NKX2-1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the NKX2-1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by TTF-1/Thyroid Transcription Factor 1/NKX2-1 HDR Plasmid (h) and TTF-1/Thyroid Transcription Factor 1/NKX2-1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by NKX2-1 homology arms to support homology-directed repair at defined NKX2-1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.